ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, cilt.78, sa.5, ss.300-304, 2015 (SCI-Expanded)
Purpose: To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).